Roche, GE launch integrated tumor diagnosis dashboard

Handshake business deal executives
The diagnostic software collaboration between Roche and GE Healthcare, first inked in January, initially focuses on oncology and critical care. (Pixabay)

Roche and GE Healthcare have launched the first fruit of their collaboration: the Navify Tumor Board 2.0, which incorporates medical image viewing with other patient data.

Aimed at multidisciplinary teams guiding cancer treatment, the product platform collates medical records from varying systems. By integrating GE’s radiology software and image storage alongside patient files and lab testing from other departments, the companies aim to save care providers time and energy.

“Workflows around tumour boards can be inefficient, and we hope this single, holistic dashboard—including patient data and images—will enable oncology teams to align more quickly on the most optimal diagnosis and treatment plan for the benefit of each patient,” Tom McGuinness, president and CEO of GE Healthcare Imaging, said in a statement.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

RELATED: Roche, GE ally to develop clinical decision support software

The collaboration, first inked in January, initially focuses on oncology and critical care, but the partnership can grow beyond those areas. The ultimate goal is a suite of products integrating in vitro lab and medical imaging data plus information on best practices, research outcomes and real-time monitoring.

RELATED: The top 10 medtech companies of 2024 | Roche | GE Healthcare

“Our mutual focus is on delivering clinical decision support solutions that enable healthcare professionals to make faster, more confident decisions, allowing more personalized treatment based on truly integrated diagnostics,” said Roche Diagnostics CEO Michael Heuer.

The new version of the cloud-based Navify Tumor Board will first be available in the U.S. and Canada, with plans to expand to additional markets in the near future, the companies said.

Suggested Articles

GenapSys has unveiled its compact, high-throughput DNA sequencer, alongside a $90 million venture capital raise to help jump-start its launch.

LivaNova plans to restructure its heart valve operations, and will drop its investigational Caisson transcatheter mitral valve replacement altogether.

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.